Page last updated: 2024-12-07

n-succinimidyl 3-(2-pyridyldithio)propionate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

n-Succinimidyl 3-(2-pyridyldithio)propionate, also known as SPDP, is a heterobifunctional crosslinker used in bioconjugation. It contains a reactive N-hydroxysuccinimide (NHS) ester that reacts with primary amines on proteins, and a 2-pyridyldithio group that can be cleaved by reduction with dithiothreitol (DTT) or other reducing agents. SPDP is commonly used to attach proteins or other molecules to solid supports or to create protein conjugates. The NHS ester reacts with lysine residues on proteins, while the 2-pyridyldithio group can be used to attach another molecule via disulfide bond formation. SPDP is widely used in research and biotechnology for applications such as antibody-drug conjugates, protein immobilization, and protein labeling.'

N-succinimidyl 3-(2-pyridyldithio)propionate: heterobifunctional reagent [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID100682
SCHEMBL ID42368
MeSH IDM0069422

Synonyms (54)

Synonym
68181-17-9
nsc-344485
nsc344485
(2,5-dioxopyrrolidin-1-yl) 3-(2-pyridyldisulfanyl)propanoate
nsc677449
3-(2-pyridyldithio)propionic acid n-hydroxysuccinimide ester
3-(2-pyridyldithio)propionic acid n-hydroxysuccinimide ester, >=95%, powder
spdp
3-(2-pyridyldithio)propionic acid n-succinimidyl ester
n-succinimidyl 3-(2-pyridyldithio)propionate
(2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate
2ohg8v08nl ,
unii-2ohg8v08nl
1-(1-oxo-3-(2-pyridyldithio)propoxy)pyrrolidine-2,5-dione
2,5-pyrrolidinedione, 1-(1-oxo-3-(2-pyridinyldithio)propoxy)-
nsc 344485
einecs 269-034-3
FT-0613591
AKOS015898576
2,5-dioxopyrrolidin-1-yl 3-(pyridin-2-yldisulfanyl)propanoate
n-succinimidyl 3-[2-pyridyldithio]-propionate
SCHEMBL42368
mfcd00009636
3-(2-pyridyldithio)-propionic acid-osu
spdp nhs ester
BP-22650
succinimidyl 3-(((2-pyridyl)thio)thio)propionate
spdp-osu
n-hydroxysuccinimidyl 3-(2-pyridyldithio)propionate
propanoic acid, 3-(2-pyridinyldithio)-, 2,5-dioxo-1-pyrrolidinyl ester
DTXSID60218366
HY-100216
CS-5649
3-(pyridin-2-yldisulfanyl)-propionic acid-osu;spdp
JWDFQMWEFLOOED-UHFFFAOYSA-N
BCP21722
spdp crosslinker pound>> spdp cross linker pound>> spdp cross-linker
(spdp);n-succinimidyl 3-[2-pyridyldithio]propionate
spdp crosslinker
AMY31084
Q27255230
A867109
3-(2-pyridyldithio)propionic acid n-succinimidyl ester;spdp
AS-55794
n-succinimidyl 3-[2-pyridyldithio]propionate
H10321
LCZC353
spdp acid nhs ester
2,5-dioxo-1-pyrrolidinyl 3-(2-pyridyldisulfanyl)propanoate
SY034492
spdp (spdp crosslinker)
spdp (2mg*5)
P2814
PD056869

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" The conjugate, PDP-Anti-AFP was then covalently coupled to the toxic abrin-A chain to synthesize immunotoxins."( Selective cytotoxic effects of immunotoxin--monoclonal anti-AFP-abrin-A chain conjugate on several human hepatoma cell lines.
Chang, KH; Chow, LP; Lin, JY, 1990
)
0.28

Pharmacokinetics

ExcerptReferenceRelevance
" Pharmacokinetic studies showed that the terminal-phase plasma half-life of ZME-RG was similar to that of ZME itself (42 h vs 50 h) and almost threefold higher than that of ZME-NG (11."( Comparative cytotoxicity and pharmacokinetics of antimelanoma immunotoxins containing either natural or recombinant gelonin.
Cheung, LH; Marks, JW; Rosenblum, MG, 1999
)
0.3

Dosage Studied

ExcerptRelevanceReference
" A suitably labelled conjugate reacted in a standardised way resulting in a reproducible dose-response curve when a positive serum was assayed in different dilutions."( A technique for preparing defined conjugates of horseradish peroxidase and immunoglobulin.
Bergquist, NR; Grundy, MS; Nilsson, P, 1981
)
0.26
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (134)

TimeframeStudies, This Drug (%)All Drugs %
pre-199045 (33.58)18.7374
1990's46 (34.33)18.2507
2000's24 (17.91)29.6817
2010's12 (8.96)24.3611
2020's7 (5.22)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 26.17

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index26.17 (24.57)
Research Supply Index4.98 (2.92)
Research Growth Index4.53 (4.65)
Search Engine Demand Index22.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (26.17)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (0.69%)6.00%
Case Studies0 (0.00%)4.05%
Observational1 (0.69%)0.25%
Other142 (98.61%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]